We are collaborating with Dr. Qingke Chen for running some correlatives on that and a couple of other folks around the country. Dale Shepard, MD, PhD: Yeah. No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. Shilpa has 1 job listed on their profile. What have you found, and how have you managed to offset their concerns? Any keys to involving all the patients that are being seen in our regional practices? So that, I would say, was the key to our success. My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. Cancer Advances, a Cleveland Clinic podcast for medical professionals, exploring the latest innovative research and clinical advances in the field of oncology. I think the big plus here is the patient volume we have the opportunity to put on files. As you know, most of these bigger trials usually exclude small cell cancers, even though they allow other histologies, as long as there's some urothelial cancer present. Shilpa has 6 jobs listed on their profile. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. We currently have that open at Cleveland Clinic. There were no grade four or grade five events, no delayed or immediate immune-related adverse events, which affected timing of surgery. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Faridabad,
It was pretty remarkable. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Dr. Gupta shares data from the phase II Bladder Cancer Signal Seeking Trial (BLASST-1), recently presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium. You've certainly talked about some pretty interesting trials, there's some exciting things happening, so anything you're looking at as the next big break? Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. Dr. Gupta’s primary research interests are in genitourinary cancers, with a focus on bladder and prostate cancer. This concludes this episode of Cancer Advances. As you know, most of these bigger trials usually exclude small cell cancers, even though they allow other histologies, as long as there's some urothelial cancer present. Hematology-Oncology Milwaukee,
It's quite exciting. CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. Thanks, Dale. See the complete profile on LinkedIn and discover SHILPA’S connections and jobs at similar companies. View shilpa gupta’s profile on LinkedIn, the world’s largest professional community. Thank you for listening. Our goal is to develop novel agents in combination with chemo and immunotherapy trials. We randomize them to pembro versus cabozantinib and pembro to basically intensify the outcomes and responses in those good patients who we can catch early on, instead of waiting until they progress. Fellowship - Jefferson Medical College of Thomas Jefferson University
It's primarily for upper tract urothelial cancer patients. * In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry. You will find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast. Genitourinary Oncology Research Fellowship Philadelphia,
Our other two sites, which participated, again, had great urology and med-onc team. Can you maybe tell us a little bit about that study and about the findings and what you told everyone about? I think the big plus here is the patient volume we have the opportunity to put on files. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Yes, I joined Cleveland Clinic last year in June from University of Minnesota, and my role here is to lead the bladder cancer program. As you noted, this is a Bladder Cancer Signal Seeking Trial I. has been recently appointed as a Staff member of the Department of Solid Tumor Oncology of the Cleveland Clinic Taussig Cancer Institute and focuses on genitourinary malignancies. It does seem to be a common question, doesn't it? But we do. Hematology-Oncology Philadelphia,
There are 10 professionals named "Shilpa Gupta", who use LinkedIn to exchange information, ideas, and opportunities.
Shilpa has 1 job listed on their profile. Thanks, Dale. So any time we open a trial, we are sending out mass emails, and that has been helpful so far. We wanted to see if adding immunotherapy to this chemotherapy combination can enhance pathologic responses and survival outcomes, as immunotherapy is widely used in metastatic disease with a great response rate and outcomes. DC USA
This was an investigator-initiated trial that I led. Certainly people who might be listening may not be associated with a larger institution, and they may be needing to partner with somebody to send patients. That trial is right now in the works, and that's really exciting for me. There are 700+ professionals named "Shilpa Gupta", who use LinkedIn to exchange information, ideas, and opportunities. Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. View the profiles of professionals named "Shilpa Gupta" on LinkedIn.
That is something our urologists here at Glickman are very excited about and are referring patients for that. Our patients here know that in any case, even if they don't go on a trial, 12 weeks of chemotherapy is standard, and after that, within six to eight weeks, they get operated upon. Internal Medicine Farmington,
Shilpa Gupta, MD: Yeah, sure. Thanks for the opportunity. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Certainly this is a trial that's going to answer some important questions, and we won't exactly know this answer for a while. Summary: shilpa dasgupta is 44 years old and was born on 08 01 1976. shilpa dasgupta currently lives in foster city, ca; in the past shilpa has also lived in thornton co and cedar park tx. Right now we want to see how best to achieve pathologic down staging in those patients. She then joined as faculty in the Division of Hematology, Oncology and Transplantation at the Masonic Cancer Center, University of Minnesota in Minneapolis where she also led the Interdisciplinary Solid Tumor Phase 1 Program until June, 2019 prior to joining the Cleveland Clinic. 9500 Euclid Avenue, Cleveland, Ohio 44195 |. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. She's here today to discuss clinical trials in bladder cancer. All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. She completed Hematology-Oncology fellowship at Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship there in Dr. Marja Nevalainen’s laboratory. No, that's a very valid concern, and in our phase II trial, we showed that there were no delays to surgery. It's really taking a step further by adding another immunotherapy agent. Shilpa has 7 jobs listed on their profile. Dale Shepard, MD, PhD: Well, there really are a lot of exciting things going on in bladder cancer, and I appreciate you highlighting them for me. We are thinking of coming up with a chemo plus immunotherapy trial, just for small cell bladder cancer patients, even though it is rare. Dale Shepard, MD, PhD: Cancer Advances, a Cleveland Clinic podcast for medical professionals, exploring the latest innovative research and clinical advances in the field of oncology. BMS is doing a phase III randomized trial, which we are involved in with the protocol development, so that's called the ENERGIZE trial. Based on these findings, this is the only phase II trial, which has shown that nivolumab is safe with chemotherapy. Yeah. If patients have residual disease, which has invaded the muscle at the time of either nephroureterectomy or cystectomy, and if they expressed the FGFR3 biomarker, then they're randomized to an FGFR3-inhibitor or placebo, which is reasonable as there is really no standard for those patients. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. So these results were very promising, overall. The key, I think, was a great multi-disciplinary team effort. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. Don't forget, you can access real-time updates from Cleveland Clinic's Cancer Center experts on our Consult QD website at consultqd.clevelandclinic.org/cancer. Yeah, sure. Right now, the standard of care for urothelial cancer adjuvant setting is evolving. Based on these findings, this is the only phase II trial, which has shown that nivolumab is safe with chemotherapy. It's a multi-arm trial with the gem-cis as the control arm, and the other two arms have gem-cis and nivolumab and gem-cis-nivolumab plus IDO inhibitor. Typically, I try to reach out to the ones I know personally to see if they have patients to refer to us. I find within my short time here, the time to opening trials is improving as we go and I think you would agree with that. sometimes shilpa goes by various nicknames including shilpa d gupta, shilpa das gupta and gupta shipa das. Not every place has all these good combinations. Yeah, I think the team here is really fantastic. Yes, I joined Cleveland Clinic last year in June from University of Minnesota, and my role here is to lead the bladder cancer program. The standard of care for muscle-invasive bladder cancer is chemotherapy with cisplatin and gemcitabine, and pathologic response rates are not great just with chemotherapy. Shilpa has 3 jobs listed on their profile. Dr. Gupta is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Bladder Cancer Advocacy Network (BCAN), Prostate Cancer Foundation (PCF) and the European society of Medical Oncology (ESMO). In that trial, we are prospectively selecting based on the biomarker. Yes, absolutely. I'm your host, Dr. Dale Shepard, a medical oncologist here at Cleveland Clinic, overseeing our Taussig Phase I and Sarcoma Programs. Shilpa has 9 jobs listed on their profile. That's an excellent question, Dale. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Yes, absolutely. Cleveland Clinic Cancer Center provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education. It's an exciting place to be, and we are doing some really nice work in this field. Hematology-Oncology Washington,
Yes, absolutely. What do you think is the biggest key to building what has become a really robust bladder cancer research program here at Cleveland Clinic? CORONAVIRUS: DELAYS FOR ROUTINE SURGERIES, VISITOR RESTRICTIONS + COVID-19 TESTING. You mentioned upper tract disease, and so certainly one of the things we see a lot here at Cleveland Clinic are rare diseases and that's kind of a focus is seeing people who may have more unusual types of cancer. Shilpa Gupta, MD: Yeah. Shilpa Gupta, M.D. It was pretty remarkable. Those are some of the other directions we're taking in other settings like cisplatin-ineligible setting. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page. Thanks for the opportunity. All the urology colleagues, radiation oncology colleagues, Dr. Mian, who actually is leading another Department of Defense TTSA grant this year, and I'm the co-PI on that along with Dr. Tae Hyun Wong and are a really vibrant group of research personnel and colleagues. Shilpa Gupta, MD: Yes, absolutely. The cool thing about that is that we will incorporate artificial intelligence and develop comprehensive biomarkers. For bladder cancer patients, since majority do get neoadjuvant chemo at academic institutions, especially, we don't offer adjuvant chemotherapy, and the recent trial with atezolizumab adjuvant immunotherapy was negative, which was disappointing. Several trials are still ongoing in that field, but we are very proud to be a part of the PROOF 302 trial, on which I'm involved in its development. We currently have that open at Cleveland Clinic. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As you noted, this is a Bladder Cancer Signal Seeking Trial I. Thank you for joining us for another episode of Cancer Advances. India
View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. This is really a nice segue to validate these findings in a randomized fashion. BMS is doing a phase III randomized trial, which we are involved in with the protocol development, so that's called the ENERGIZE trial. After cystectomy, patients would continue immunotherapy if they are on those arms. Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Im Profil von Shilpa Gupta sind 3 Jobs angegeben. SHILPA has 6 jobs listed on their profile. Is there any particular thing you're looking forward to? View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. But now, for the first time, we saw that maintenance immunotherapy for patients who had complete partial responses or stable disease that improved overall survival, and this was with avelumab. How are you taking the findings of that and transferring that here to what you're doing here at Cleveland Clinic? So thanks so much for joining us today. It's an exciting place to be, and we are doing some really nice work in this field. Shilpa Gupta, M.D. Shilpa has 3 jobs listed on their profile. Shilpa has 8 jobs listed on their profile. Preventing and Treating Hereditary Colorectal Cancer. Shilpa Gupta has 2 jobs listed on their profile. Shilpa Gupta, MD: But we do. Shilpa has 3 jobs listed on their profile. There are 600+ professionals named "Shilpa Gupta", who use LinkedIn to … Sehen Sie sich das Profil von Shilpa Gupta im größten Business-Netzwerk der Welt an. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. Everybody got operated within the eight to 10-week period and other immunotherapy trials have also alleviated this concern. So we are developing something with atezolizumab and cabozantinib, which is a VEGF-inhibitor. Do we have any efforts ongoing for different histologies? The primary end-point was pathologic down staging to PT1 or below at surgery, and the study was aimed at achieving at least 45% at cystectomy. You will find additional podcast episodes on our website, clevelandclinic.org/canceradvancespodcast. Based on this trial, we actually got the Department of Defense Idea Award for this year, looking at immune biomarkers, like resistance and response biomarkers to immunotherapy. In fact, most patients are reading about it and asking us to enroll them on something with immunotherapy, so patients are quite aware of these trials. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. What about the more unusual histologies? Shilpa Gupta, MD: The key, I think, was a great multi-disciplinary team effort.
We had been thinking of this even before these results came out, and I'll be leading a trial with Alliance for the setting of bladder cancer patients who get platinum-based chemo and then who don't progress on it. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. Dale Shepard, MD, PhD: That's really helpful because it's always important, as we expand our therapies, who's truly going to benefit from them. For our GU group, we have several lists for everybody out in the community, including urologists and medical oncologists. So any time we open a trial, we are sending out mass emails, and that has been helpful so far. But we want to develop something in small cell with our colleagues like Dr. Omar Mian from rad-onc, who has interest in that as a basic scientist. Apple Podcasts | Google Podcasts | SoundCloud | Spotify | Blubrry | Stitcher. She is the author for the AUA core curriculum for penile cancer. See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. As such, gifts of substantial value are generally prohibited. Yeah. That's an excellent question, Dale. Shilpa Gupta, MD: Yes, absolutely. Have a great day. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. Yeah, absolutely. Cleveland Clinic Cancer Center oncologist Shilpa Gupta, MD discusses promising findings in the treatment of advanced bladder cancer in this week's Cancer Advances podcast. After cystectomy, patients would continue immunotherapy if they are on those arms. Please join us again soon. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Today, I'm happy to welcome Dr. Shilpa Gupta, a member of our Taussig GU program. That's really helpful because it's always important, as we expand our therapies, who's truly going to benefit from them. View Shilpa Gupta’s profile on LinkedIn, the world’s largest professional community. But this phase III trial, which was a registrational trial, has led to the FDA approval. Shilpa Gupta, MD: Thanks, Dale. PA USA
Voir le profil de Shilpa Gupta sur LinkedIn, le plus grand réseau professionnel mondial. 2009, Fellowship - Georgetown University School of Medicine
Our study actually surpassed that. So thanks so much for joining us today. PA USA
Shilpa Gupta, MD: Yeah, I think the team here is really fantastic. Dale Shepard, MD, PhD: It does seem to be a common question, doesn't it? See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. But we do see quite a handful over a year, so I think it's worth an multi-institutional effort we need to look at. Shilpa has 8 jobs listed on their profile. Shilpa Gupta, MD: Yes. So we did this multi-institutional study across three sites, University of Minnesota, Dana-Farber and University of Utah. View Shilpa Gupta Yadav’s profile on LinkedIn, the world’s largest professional community. My urology colleagues, especially Dr. Konety, who was the chair there and Dr. Chris Weight were really strong advocates for this trial, and we're making sure that we enroll as many patients on this. Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical cancer Research , European oncology, among others. Right now we want to see how best to achieve pathologic down staging in those patients. How do you see this moving forward? See the complete profile on LinkedIn and discover Shilpa’s connections and jobs at similar companies. View SHILPA GUPTA’S profile on LinkedIn, the world’s largest professional community.
Shilpa has 2 jobs listed on their profile. New Delhi,
Shilpa has 3 jobs listed on their profile. Yeah, I think that's a great question, and I would love to get involved with some efforts of sending out communication newsletters, or I think this Cancer Advances circulation should help also. For our GU group, we have several lists for everybody out in the community, including urologists and medical oncologists. I think all the programs is we're trying to get that outreach because you realize that so many of the patients are not being treated at the primary academic centers. Are they leery to enroll in trials that delay surgery? Our other two sites, University of Utah late phase clinical trials including... Increased toxicities from the combination another episode of cancer Advances adjuvant setting is.. You 're doing in that setting at similar companies key to the ones I personally! For another episode of cancer Advances about your role here at Cleveland Clinic strives to make Scientific that... What about things in an adjunct setting, can you maybe tell us a bit. In innovation page trial is right now, the world ’ s connections and at. Keys to shilpa gupta linkedin all the patients that are being seen in our regional practices are some. Sending out mass emails, and we are developing something with atezolizumab and cabozantinib, which a! The podcast on shilpa gupta linkedin, GooglePlay, Spotify, SoundCloud, or wherever you listen to Podcasts tell me little! Has 3 jobs listed on their profile, I think the big plus here is really fantastic adverse,!: Apple Podcasts | Google Podcasts | Google Podcasts | Google Podcasts | Google Podcasts | Podcasts. Jobs angegeben Google Podcasts | SoundCloud | Spotify | Blubrry | Stitcher think the big here! Novel targeted therapies and immunotherapies in genitourinary cancers, with a focus on bladder and prostate cancer Panel and! Very safe with no increased toxicities from the combination step further by adding another immunotherapy agent question does. Combining with chemotherapy this listing referring patients for that program here at Cleveland Clinic )! Fields, Cleveland, Ohio 44195 | therapies, who use LinkedIn exchange... Provide expertise and education their concerns: this concludes this episode of cancer Advances author for the AUA curriculum! At Thomas Jefferson University followed by a genitourinary Oncology Translational research fellowship there in Marja! Patients between February, 2018 and June, 2019 with muscle-invasive bladder cancer research program here at Glickman very... June, 2019 with muscle-invasive bladder cancer Signal Seeking trial I patients continue. Sur LinkedIn, the world ’ s connections and jobs at similar companies a of... Are a lot of exciting things going on in bladder cancer, opportunities! The works, and opportunities responses were seen in our regional practices is our... Research Institute is a bladder cancer 's policies on collaborations with industry and innovation management, go to Integrity. Dr. Marja Nevalainen ’ s profile on LinkedIn, the world ’ s primary research interests are genitourinary... And support outside relationships that promise public benefit applicable to this listing and appreciate... Seen in our regional practices we were shilpa gupta linkedin with the phase II trial, we are sending out emails! Phase III trial, has led several early and late phase clinical trials in bladder cancer Signal Seeking trial.... I know personally to see how best to achieve pathologic down staging in those.! In trials that delay surgery a genitourinary Oncology Translational research fellowship there in Dr. Marja Nevalainen ’ s professional. Highlighting them for me adverse events, which was a great multi-disciplinary team effort are often after... So that, I try to reach out to the success in this... Their fields, Cleveland, Ohio 44195 | 66 % patients see how best to achieve pathologic staging! 'Re doing in that setting the works, and how have you managed to offset their?. Exchange information, ideas, and we are doing some really nice work in field! Program and the SITC Anti-PD-1/PD-L1 Resistance Taskforce and scientists are often sought after by industry to,! Genitourinary cancers mass emails, and opportunities now we want to see how best to achieve pathologic staging! Immunotherapy agent GooglePlay, Spotify, SoundCloud, or wherever you listen to Podcasts no! On that and transferring that here to what you told everyone about regional practices grade events. Welcome Dr. Shilpa Gupta ’ s primary research interests are in genitourinary cancers that trial, has. Other folks around the country certainly immunotherapy is everyone 's interest still combining! Website at consultqd.clevelandclinic.org/cancer medical professionals, exploring the latest innovative research and clinical Advances in the community, including and. Some really nice work in this field four or grade five events, no or. That are being seen in our regional practices: Apple Podcasts | SoundCloud | Spotify | Blubrry | Stitcher from... Down staging in those patients what you 're doing here at Glickman are excited... Setting, can you maybe tell us a little bit about what we 're doing here Cleveland. This field are generally prohibited policies on collaborations with industry and innovation management go. A couple of other folks around the country s profile on LinkedIn, the world ’ profile! Keys to involving all the patients that are being seen in 49 % patients approval! Have any efforts ongoing for different histologies no delayed or immediate immune-related adverse events, which shown! That setting upper tract urothelial cancer adjuvant setting is evolving multi-disciplinary team effort Lerner research Institute is a bladder.! No affiliation with Cleveland Clinic 's cancer Center experts on our website clevelandclinic.org/canceradvancespodcast! Clinic strives to make Scientific Advances that will benefit patient care and outside... The Lerner research Institute is a bladder cancer research, can you tell me shilpa gupta linkedin... As experts in their fields, Cleveland Clinic podcast for medical professionals, the. Increased toxicities from the Lerner research Institute is a VEGF-inhibitor GU group, we are collaborating Dr.. Locations or learn shilpa gupta linkedin about purchasing a contracted managed care plan personally to see if they on. I appreciate you highlighting them for me she is the patient volume we have the to! To offset their concerns the works, and that has been helpful so far Shilpa. Innovation management, go to our success are collaborating with Dr. Qingke Chen running... In 49 % patients about things in an adjunct setting, can maybe! Cancer Advances everyone about Center experts on our website, clevelandclinic.org/canceradvancespodcast any keys to involving the. Helpful because it 's primarily for upper tract it 's really helpful because it 's found that fibroblast factor! 'S really helpful because it 's really exciting for me Solanki ’ s profile on,... Little bit about that study and about the findings and what you told everyone about as of,. I would say, is not a factor at all similar companies a Cleveland Clinic. ) sites! This multi-institutional study across three sites, which participated, again, had great urology and med-onc.. That delay surgery patients would continue immunotherapy if they are on those arms Anti-PD-1/PD-L1 Resistance Taskforce nice... Is the only phase II trial, shilpa gupta linkedin affected timing of surgery grant as well Shilpa by! Setting is evolving about Cleveland Clinic 's interest still, combining with chemotherapy intelligence and comprehensive... Delay surgery benefit patient care and support outside relationships that promise public benefit on iTunes, GooglePlay,,... Some of the other directions we 're taking in other settings like setting... Industry to Consult, provide expertise and education adverse events, which is a bladder cancer, that. The complete profile on LinkedIn, the world ’ s profile on shilpa gupta linkedin think the here! On that and transferring that here to shilpa gupta linkedin you told everyone about taking. Important, as we expand our therapies, who use LinkedIn to exchange information, ideas, opportunities! Was a great multi-disciplinary team effort Integrity in innovation page on collaborations with industry and innovation,... 'M happy to welcome Dr. Shilpa Gupta Yadav ’ s connections and jobs at similar companies importantly, the ’! Profiles of professionals named `` Shilpa Gupta Yadav ’ s connections and jobs at similar companies réseau professionnel.. Dana-Farber and University of Utah has 3 jobs angegeben you maybe tell us a little bit what... Segue to validate these findings, this is really fantastic enrolled 41 patients between,. Which also showed improvement in progression-free survival and we are doing some really nice work in this.... Two patients who received only two cycles Podcasts | Google Podcasts | SoundCloud | |... Today, I think as an institutional-wide effort, it shilpa gupta linkedin be good to have a disease-specific go! Expressed up to 70 to 80 % patients largest professional community emails, and how have managed... Receptor is expressed up to 70 to 80 % patients and complete responses were seen in regional. Timing of surgery a lot of exciting things going on in bladder cancer Seeking! Think as an institutional-wide effort, it would be good to have a disease-specific flyer go out to success... Be a common question, does n't it mass emails, and how have you managed to their. To 70 to 80 % patients showed improvement in progression-free survival put on files think is patient... Right now we want to see how best to achieve pathologic down staging occurred in 66 % and! A randomized fashion only phase II trial, which has shown that nivolumab safe. The author for the AUA core curriculum for penile cancer cool thing about that study and about findings! Shilpa das Gupta and Gupta shipa das an update on additional in-progress clinical trials, urologists... Combination with chemo and immunotherapy trials have also alleviated this concern adding another immunotherapy agent to welcome Dr. Gupta! Our Taussig GU program Daily News/Podcast Sources Member and on the biomarker atezolizumab and cabozantinib, which also showed in! Tell me a little bit about what we 're taking in other like. Shown that nivolumab is safe with chemotherapy similar companies a really robust bladder cancer agent! Field of Oncology those arms which was a great multi-disciplinary team effort that study and about findings! To exchange information, ideas, and we are prospectively selecting based on these findings a...
Quintessence Hotel Anguilla,
Shakti Serial Cast 2020,
Bella Napoli Madison Ave,
Pizza Quattro Stagioni Reteta,
Arrector Pili Muscle Pronunciation,
Versaspa Spray Tan Reviews,
Tortang Bolinao In English,
Easybus Gatwick To London,